Rhythm Pharmaceuticals (RYTM) Return on Invested Capital (2025 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Return on Invested Capital of 0.09% for Q1 2026, up 65.0% year-over-year from 0.05% in Q1 2025, and up 29.74% quarter-over-quarter from 0.13% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Return on Invested Capital (2025 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Return on Invested Capital for 2 consecutive years, with 0.09% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Invested Capital rose 65.0% year-over-year to 0.09%; the TTM figure through Mar 2026 stood at 0.09% (up 65.0% YoY), while the FY2025 annual figure was 0.44%, changed N/A from the prior year.
- Return on Invested Capital rose to 0.09% in Q1 2026 per RYTM's latest filing, from 0.13% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.09% in Q1 2026 and bottomed at 0.74% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.05% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.35% |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | -0.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.06% |
| Mar 31, 2026 | -0.09% |
| Dec 31, 2025 | -0.13% |
| Sep 30, 2025 | -0.19% |
| Jun 30, 2025 | -0.35% |
| Mar 31, 2025 | -0.74% |